Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 298

1.

A group I metabotropic glutamate receptor controls synaptic gain between rods and rod bipolar cells in the mouse retina.

Hellmer CB, Clemons MR, Nawy S, Ichinose T.

Physiol Rep. 2018 Oct;6(20):e13885. doi: 10.14814/phy2.13885.

PMID:
30338673
2.

Physician Survey of Timing of Adjuvant Endocrine Therapy Relative to Radiotherapy in Early Stage Breast Cancer Patients.

McGee SF, Vandermeer L, Mazzarello S, Sienkiewicz M, Stober C, Hutton B, Fergusson D, Hilton J, Caudrelier JM, Blanchette P, Clemons M.

Clin Breast Cancer. 2018 Sep 4. pii: S1526-8209(18)30204-0. doi: 10.1016/j.clbc.2018.08.012. [Epub ahead of print]

PMID:
30318304
3.

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.

Fernandes R, Mazzarello S, Stober C, Ibrahim MFK, Dudani S, Perdrizet K, Majeed H, Vandermeer L, Shorr R, Hutton B, Fergusson D, Gyawali B, Clemons M.

J Glob Oncol. 2018 Sep;(4):1-8. doi: 10.1200/JGO.2016.008540. Epub 2017 Apr 21.

PMID:
30241156
4.

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J.

Eur J Cancer. 2018 Nov;103:147-154. doi: 10.1016/j.ejca.2018.08.002. Epub 2018 Sep 18.

PMID:
30241001
5.

Perceptions of vascular access for intravenous systemic therapy and risk factors for lymphedema in early-stage breast cancer-a patient survey.

LeVasseur N, Stober C, Ibrahim M, Gertler S, Hilton J, Robinson A, McDiarmid S, Fergusson D, Mazzarello S, Hutton B, Joy AA, McInnes M, Clemons M.

Curr Oncol. 2018 Aug;25(4):e305-e310. doi: 10.3747/co.25.3911. Epub 2018 Aug 14.

6.

Optimizing vascular access for patients receiving intravenous systemic therapy for early-stage breast cancer-a survey of oncology nurses and physicians.

LeVasseur N, Stober C, Daigle K, Robinson A, McDiarmid S, Mazzarello S, Hutton B, Joy A, Fergusson D, Hilton J, McInnes M, Clemons M.

Curr Oncol. 2018 Aug;25(4):e298-e304. doi: 10.3747/co.25.3903. Epub 2018 Aug 14.

7.

Unnecessary variation in practice: how to improve cancer care through pragmatic trials.

LeVasseur N, Fergusson D, Clemons M.

Curr Oncol. 2018 Aug;25(4):e263-e264. doi: 10.3747/co.25.3922. Epub 2018 Aug 14. No abstract available.

8.

Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).

Clemons M, Mazzarello S, Hilton J, Joy A, Price-Hiller J, Zhu X, Verma S, Kehoe A, Ibrahim MF, Sienkiewicz M, Stober C, Vandermeer L, Hutton B, Mallick R, Fergusson D.

Support Care Cancer. 2018 Aug 11. doi: 10.1007/s00520-018-4408-6. [Epub ahead of print]

PMID:
30099602
9.

De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times?

Awan AA, Paterson A, Clemons M.

J Oncol Pract. 2018 Aug;14(8):465-467. doi: 10.1200/JOP.18.00393. No abstract available.

PMID:
30096270
10.

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).

Hilton J, Stober C, Mazzarello S, Vandermeer L, Fergusson D, Hutton B, Clemons M.

PLoS One. 2018 Jul 24;13(7):e0199297. doi: 10.1371/journal.pone.0199297. eCollection 2018.

11.

Optimal sequence of adjuvant endocrine and radiation therapy in early-stage breast cancer - A systematic review.

McGee SF, Mazzarello S, Caudrelier JM, Lima MAG, Hutton B, Sienkiewicz M, Stober C, Fernandes R, Ibrahim MFK, Vandermeer L, Hilton J, Shorr R, Fergusson D, Clemons M.

Cancer Treat Rev. 2018 Sep;69:132-142. doi: 10.1016/j.ctrv.2018.06.015. Epub 2018 Jun 28. Review.

PMID:
30014951
12.

Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review.

Robinson A, Souied O, Bota AB, Levasseur N, Stober C, Hilton J, Kamel D, Hutton B, Vandermeer L, Mazzarello S, Joy AA, Fergusson D, McDiarmid S, McInnes M, Shorr R, Clemons M.

Breast Cancer Res Treat. 2018 Oct;171(3):607-620. doi: 10.1007/s10549-018-4868-x. Epub 2018 Jul 4.

PMID:
29974358
13.

Poor outcomes after venous thromboembolism in cancer patients: It's time to change practice.

Delluc A, Clemons M.

Thromb Res. 2018 Jun 2. pii: S0049-3848(18)30377-3. doi: 10.1016/j.thromres.2018.06.003. [Epub ahead of print] No abstract available.

PMID:
29880445
14.

The importance of greater speed in drug development for advanced malignancies.

Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R.

Cancer Med. 2018 May;7(5):1824-1836. doi: 10.1002/cam4.1454. Epub 2018 Mar 30.

15.

Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study.

Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK, Canil C, Ong M, Stober C, Vandermeer L, Hutton B, da Costa M, Damaraju S, Clemons M.

Support Care Cancer. 2018 Sep;26(9):3073-3081. doi: 10.1007/s00520-018-4161-x. Epub 2018 Mar 21.

PMID:
29564623
16.

Guidelines versus individualized care for the management of CINV.

Clemons M.

Support Care Cancer. 2018 Mar;26(Suppl 1):11-17. doi: 10.1007/s00520-018-4115-3. Epub 2018 Mar 19.

17.

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-CME information.

Aapro M, Clemons M, Schwartzberg L, Warr D.

Support Care Cancer. 2018 Mar;26(Suppl 1):1-2. doi: 10.1007/s00520-018-4122-4. Epub 2018 Mar 19. No abstract available.

PMID:
29556807
18.

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, Ellis MJ, Pritchard KI, Clemons MJ, Badovinac-Crnjevic T, Han L, Gelmon KA, Rabaglio M, Elliott C, Shepherd LE, Goss PE.

J Natl Cancer Inst. 2018 Sep 1;110(9):1003-1008. doi: 10.1093/jnci/djy017.

PMID:
29554282
19.

Should de-escalation of bone-targeting agents be standard of care?

Awan A, Hutton B, Clemons M.

Ann Oncol. 2018 May 1;29(5):1333-1334. doi: 10.1093/annonc/mdy068. No abstract available.

PMID:
29529190
20.

Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients.

Hilton J, Vandermeer L, Sienkiewicz M, Mazzarello S, Hutton B, Stober C, Fergusson D, Blanchette P, Joy AA, Brianne Bota A, Clemons M.

Support Care Cancer. 2018 Jul;26(7):2323-2331. doi: 10.1007/s00520-018-4074-8. Epub 2018 Feb 6.

PMID:
29411131
21.

A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer.

Ibrahim MFK, Hilton J, Mazzarello S, Fergusson D, Hutton B, Robinson A, Califaretti N, Hsu T, Gertler S, Mates M, Stober C, Vandermeer L, Mallick R, Clemons M.

Breast Cancer Res Treat. 2018 Apr;168(2):371-379. doi: 10.1007/s10549-017-4604-y. Epub 2017 Dec 6.

PMID:
29214415
22.

Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy.

Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Quang LH, Han PT, Khoa PH, Dinh NV, To TV, Clemons M, Smith IE, Dowsett M.

NPJ Breast Cancer. 2017 Nov 27;3:47. doi: 10.1038/s41523-017-0049-z. eCollection 2017.

23.

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.

Hilton JF, Clemons M, Pond G, Zhao H, Mazzarello S, Vandermeer L, Addison CL.

J Bone Oncol. 2017 Nov 8;10:6-13. doi: 10.1016/j.jbo.2017.11.001. eCollection 2018 Mar.

24.

What we learned in kindergarten: five tips for collaboration in oncology.

Arnaout A, Joy AA, Juliao M, Clemons M.

Curr Oncol. 2017 Oct;24(5):e437-e440. doi: 10.3747/co.24.3675. Epub 2017 Oct 25. No abstract available.

25.

Generating Medical Student Interest in the Field of Radiology.

Taylor CS, Weatherly B, Farley EP, Clemons MP, Watts J, Vijayakumar V.

J Am Coll Radiol. 2018 Feb;15(2):340-342. doi: 10.1016/j.jacr.2017.08.018. Epub 2017 Oct 24. No abstract available.

PMID:
29079247
26.

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.

Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B.

J Clin Oncol. 2017 Dec 10;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16.

PMID:
29035643
27.

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L.

Breast Cancer Res Treat. 2018 Jan;167(2):485-493. doi: 10.1007/s10549-017-4538-4. Epub 2017 Oct 13.

PMID:
29027598
28.

Physician "out of office" alert: does it work?

Clemons M, Joy AA, Hilton J, Arnaout A, Brackstone M, Wheatley-Price P, Stober C, Dinniwell R, Mazzarello S, da Costa M, Hutton B.

Curr Oncol. 2017 Jun;24(3):e176-e179. doi: 10.3747/co.24.3548. Epub 2017 Jun 27. No abstract available.

29.

Reply to T.J. Powles et al.

Dhesy-Thind S, Fletcher GG, Clemons M, Van Poznak C; Cancer Care Ontario–American Society of Clinical Oncology Adjuvant Bone-Modifying Agents Panel.

J Clin Oncol. 2017 Aug 10;35(23):2720-2721. doi: 10.1200/JCO.2017.73.8567. Epub 2017 Jun 27. No abstract available.

PMID:
28654367
30.

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH.

J Clin Oncol. 2017 Jun 20;35(18):2062-2081. doi: 10.1200/JCO.2016.70.7257. Epub 2017 Mar 6. Review.

PMID:
28618241
31.

Is This Conference for Real? Navigating Presumed Predatory Conference Invitations.

Cobey KD, de Costa E Silva M, Mazzarello S, Stober C, Hutton B, Moher D, Clemons M.

J Oncol Pract. 2017 Jul;13(7):410-413. doi: 10.1200/JOP.2017.021469. Epub 2017 Jun 14. No abstract available.

PMID:
28613970
32.

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M.

Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30.

33.

The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting.

Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M.

Ann Oncol. 2017 Jun 1;28(6):1260-1267. doi: 10.1093/annonc/mdx100.

34.

A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach.

Thavorn K, Coyle D, Hoch JS, Vandermeer L, Mazzarello S, Wang Z, Dranitsaris G, Fergusson D, Clemons M.

Support Care Cancer. 2017 Aug;25(8):2505-2513. doi: 10.1007/s00520-017-3658-z. Epub 2017 Mar 9.

PMID:
28281050
35.

Predatory Invitations from Journals: More Than Just a Nuisance?

Clemons M, de Costa E Silva M, Joy AA, Cobey KD, Mazzarello S, Stober C, Hutton B.

Oncologist. 2017 Feb;22(2):236-240. doi: 10.1634/theoncologist.2016-0371. Epub 2017 Feb 10.

36.

Low temperature thermal ALD of a SiNx interfacial diffusion barrier and interface passivation layer on SixGe1- x(001) and SixGe1- x(110).

Edmonds M, Sardashti K, Wolf S, Chagarov E, Clemons M, Kent T, Park JH, Tang K, McIntyre PC, Yoshida N, Dong L, Holmes R, Alvarez D, Kummel AC.

J Chem Phys. 2017 Feb 7;146(5):052820. doi: 10.1063/1.4975081.

PMID:
28178835
37.

Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.

Jacobs C, Clemons M, Mazzarello S, Hutton B, Joy AA, Brackstone M, Freedman O, Vandermeer L, Ibrahim M, Fergusson D, Hilton J.

Support Care Cancer. 2017 Jun;25(6):1881-1886. doi: 10.1007/s00520-017-3580-4. Epub 2017 Jan 27.

PMID:
28127659
38.

Strategies for obtaining bone biopsy specimens from breast cancer patients - Past experience and future directions.

Ibrahim MF, Hilton J, Addison C, Robertson S, Werier J, Mazzarello S, Vandermeer L, Jacobs C, Clemons M.

J Bone Oncol. 2016 Jul 7;5(4):180-184. doi: 10.1016/j.jbo.2016.07.001. eCollection 2016 Nov.

39.

A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer.

Addison CL, Simos D, Wang Z, Pond G, Smith S, Robertson S, Mazzarello S, Singh G, Vandermeer L, Fernandes R, Iyengar A, Verma S, Clemons M.

J Bone Oncol. 2016 Jul 1;5(4):173-179. doi: 10.1016/j.jbo.2016.06.003. eCollection 2016 Nov.

40.

Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.

Fernandes R, Mazzarello S, Stober C, Vandermeer L, Dudani S, Ibrahim MF, Majeed H, Perdrizet K, Shorr R, Hutton B, Fergusson D, Clemons M.

Breast Cancer Res Treat. 2017 Jan;161(1):1-10. doi: 10.1007/s10549-016-4028-0. Epub 2016 Oct 25. Review.

PMID:
27783280
41.

Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.

LeVasseur N, Clemons M, Hutton B, Shorr R, Jacobs C.

Cancer Treat Rev. 2016 Nov;50:183-193. doi: 10.1016/j.ctrv.2016.09.013. Epub 2016 Sep 20. Review.

PMID:
27716496
42.

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.

Johnston S, Basik M, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M, Dreosti L, Mann H, Stuart M, Cristofanilli M.

Breast Cancer Res Treat. 2016 Nov;160(1):91-99. Epub 2016 Sep 21.

PMID:
27654971
43.

Novel Methodology for Comparing Standard-of-Care Interventions in Patients With Cancer.

Hilton J, Mazzarello S, Fergusson D, Joy AA, Robinson A, Arnaout A, Hutton B, Vandermeer L, Clemons M.

J Oncol Pract. 2016 Dec;12(12):e1016-e1024. Epub 2016 Sep 30.

PMID:
27650842
44.

A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer.

Fernandes R, Mazzarello S, Hutton B, Shorr R, Ibrahim MFK, Jacobs C, Ong M, Clemons M.

Clin Genitourin Cancer. 2017 Feb;15(1):1-6. doi: 10.1016/j.clgc.2016.07.018. Epub 2016 Jul 28. Review.

PMID:
27554586
45.

Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patients-A Systematic Review.

Dudani S, Mazzarello S, Hilton J, Hutton B, Vandermeer L, Fernandes R, Ibrahim MF, Smith S, Majeed H, Al-Baimani K, Caudrelier JM, Shorr R, Clemons M.

Clin Breast Cancer. 2016 Dec;16(6):456-470. doi: 10.1016/j.clbc.2016.07.014. Epub 2016 Jul 28. Review.

PMID:
27553811
46.

Will oncologists applaud the Paris Accord? Time to rethink global mega-conferences.

Jacobs C, Joy AA, Clemons M.

Curr Oncol. 2016 Aug;23(4):223-4. doi: 10.3747/co.23.3169. Epub 2016 Aug 12. No abstract available.

47.

Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.

Yeung C, Hilton J, Clemons M, Mazzarello S, Hutton B, Haggar F, Addison CL, Kuchuk I, Zhu X, Gelmon K, Arnaout A.

Cancer Metastasis Rev. 2016 Sep;35(3):427-37. doi: 10.1007/s10555-016-9631-3. Review.

PMID:
27405651
48.

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.

Chadha AS, Skinner HD, Gunther JR, Munsell MF, Das P, Minsky BD, Delclos ME, Chatterjee D, Wang H, Clemons M, George G, Singh PK, Katz MH, Fleming JB, Javle MM, Wolff RA, Varadhachary GR, Crane CH, Krishnan S.

PLoS One. 2016 Jun 23;11(6):e0156910. doi: 10.1371/journal.pone.0156910. eCollection 2016.

49.

Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS).

Fernandes R, Siegel P, Komarova S, Hilton J, Addison C, Ibrahim MF, Werier J, Dennis K, Singh G, Amir E, Jarvis V, Emmenegger U, Mazzarello S, Clemons M.

J Bone Oncol. 2016 Feb 23;5(2):57-62. doi: 10.1016/j.jbo.2016.02.004. eCollection 2016 Jun. Review.

50.

Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study.

Arnaout A, Kuchuk I, Bouganim N, Pond G, Verma S, Segal R, Dent S, Gertler S, Song X, Kanji F, Clemons M.

Curr Oncol. 2016 Jun;23(3):e276-9. doi: 10.3747/co.23.2394. Epub 2016 Jun 9.

Supplemental Content

Loading ...
Support Center